A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

Nintedanib

Trial Locations (1)

20123

Pneumology unit, Milan

All Listed Sponsors
lead

IRCCS Multimedica

OTHER

NCT03062943 - A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | Biotech Hunter | Biotech Hunter